Cipla Limited — Potassium Exporter Profile
Indian Pharmaceutical Exporter · #11 for Potassium · $10.6M export value · DGFT Verified
Cipla Limited is the #11 Indian exporter of Potassium with $10.6M in export value and 211 verified shipments. Cipla Limited holds a 1.6% market share in Potassium exports across 10 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Potassium Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Potassium?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $4.8M | 125 | 54.6% |
| UNITED STATES | $1.2M | 30 | 13.4% |
| CANADA | $954.4K | 60 | 10.8% |
| TURKEY | $904.3K | 33 | 10.3% |
| MADAGASCAR | $554.1K | 42 | 6.3% |
| UNITED ARAB EMIRATES | $119.5K | 15 | 1.4% |
| AUSTRALIA | $112.9K | 11 | 1.3% |
| KENYA | $47.7K | 4 | 0.5% |
| TRINIDAD & TOBAGO | $46.1K | 5 | 0.5% |
| MAURITIUS | $34.7K | 7 | 0.4% |
Cipla Limited exports Potassium to 14 countries. The largest destination is SRI LANKA accounting for 54.6% of Cipla Limited's Potassium shipments, followed by UNITED STATES (13.4%) and CANADA (10.8%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Potassium from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $3.0M | 73 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $1.7M | 49 |
| PALADIN LABS INC | CANADA | $954.4K | 60 |
| HIGEN COMPANY | TURKEY | $582.4K | 24 |
| WOCKHARDT BIO AG C O UPS | UNITED STATES | $346.1K | 10 |
| OPHAM | MADAGASCAR | $327.2K | 23 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $300.0K | 6 |
| WOCKHARDT BIO AG | UNITED STATES | $294.3K | 8 |
| ROZ LOGISTICS | TURKEY | $246.9K | 7 |
| WOCKHARDT BIO AG C O UPS SUPPLY CHA | UNITED STATES | $194.3K | 5 |
Cipla Limited supplies Potassium to 31 buyers globally. The largest buyer is BREATHEFREE LANKA PVT LTD (SRI LANKA), followed by BREATHEFREE LANKA PRIVATE LIMITED (SRI LANKA) and PALADIN LABS INC (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Potassium Export Value and How Much Does Cipla Limited Contribute?
India exported $225.9M worth of Potassium through 15,000 shipments from 877 suppliers to 177 countries, serving 2,474 buyers globally. Cipla Limited contributes $10.6M to this total, accounting for 1.6% of India's Potassium exports. Cipla Limited ships Potassium to 14 countries through 31 buyers.
What Is the Average Shipment Value for Cipla Limited's Potassium Exports?
Cipla Limited's average Potassium shipment value is $50.0K per consignment, based on 211 shipments totaling $10.6M. The largest destination is SRI LANKA (54.6% of Cipla Limited's Potassium exports).
How Does Cipla Limited Compare to Other Indian Potassium Exporters?
Cipla Limited ranks #11 among 877 Indian Potassium exporters with a 1.6% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($67.3M), AUROBINDO PHARMA LIMITED ($29.9M), MICRO LABS LIMITED ($25.1M). Cipla Limited processed 211 shipments to 10 destination countries.
What Potassium Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ZAART 50 TABLETS LOSARTAN POTASSIUM 50 | $653.2K | 14 |
| AMOXICILLIN & CLAVULANATE POTASSIUM FOR | $540.5K | 15 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50 | $389.8K | 9 |
| ZAART 25 TAB (LOSARTAN POTASSIUM 25MG) ( | $210.0K | 5 |
| AMOXICILLIN&CLAVULANATE POTASSIUM FOR ORAL SUSPENSION 250MG/62.5MG; NDC NO.60432065-00;HC CODE:3004.10.5045 PACK SIZE:1 | $208.6K | 6 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50M | $184.8K | 12 |
| NOVACLAV 625 TABLET(AMOXYCILLIN TRIHYDRATE 500MG+CLAVULANATE POTASSIUM 125MG) INV.QTY.66560 PACK 1X10'S=66560 | $163.1K | 9 |
| ZAART 50 TABLETS LOSARTAN POTASSIUM 50 MG INV QTY 30240 PACK 10X10 S 3024000 NOS | $150.0K | 3 |
| Micro K Extencaps 600mg Potassium Chloride 3696 PACKS X1X100S | $147.7K | 9 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) . (INV.QTY.30408 PACK 10 X 10S=3040800 NOS)NOS | $115.0K | 3 |
Cipla Limited exports 164 distinct Potassium formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ZAART 50 TABLETS LOSARTAN POTASSIUM 50 with 14 shipments worth $653.2K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Potassium to Key Markets
What Cipla Limited must comply with to export Potassium to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Potassium Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | ZYDUS LIFESCIENCES LIMITED | $13.1M | 262 | 12 | $50.0K |
| 9 | CAPLIN POINT LABORATORIES LIMITED | $11.3M | 225 | 10 | $50.0K |
| 11 | CIPLA LIMITED ★ | $10.6M | 211 | 10 | $50.0K |
| 14 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $9.2M | 184 | 1 | $50.0K |
| 4 | RUBICON RESEARCH PRIVATE LIMITED | $7.2M | 143 | 1 | $50.0K |
Cipla Limited ranks #11 among 877 Indian Potassium exporters. Average shipment value of $50.0K compared to the market average of $257.6K. The closest competitors by value are ZYDUS LIFESCIENCES LIMITED and CAPLIN POINT LABORATORIES LIMITED.
Which Indian Ports Ship Potassium Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,108 | 7.4% |
| SAHAR AIR | 916 | 6.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 911 | 6.1% |
| DELHI AIR CARGO ACC (INDEL4) | 791 | 5.3% |
| HYDERABAD ICD (INSNF6) | 767 | 5.1% |
| DELHI AIR | 715 | 4.8% |
| JNPT/ NHAVA SHEVA SEA | 645 | 4.3% |
| HYDERABAD ICD | 644 | 4.3% |
What Other Nutritional Supplements Products Does Cipla Limited Export?
Cipla Limited also exports these nutritional supplements products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Potassium Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Potassium, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Potassium — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Potassium shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 338 individual customs records matching Cipla Limited exporting Potassium, covering 164 formulations to 14 countries via 31 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 177+ countries, 2,474+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Potassium Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Potassium exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Potassium Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Potassium. For current shipment-level data, contact TransData Nexus.